All news

A director proposes selling 22,583 Nurix Therapeutics (Nasdaq: NRIX) shares acquired by exercising options.

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

Julia Gregory, a director at Nurix Therapeutics, proposes to sell 22,583 common shares of the company, valued at $528,528.02. The shares were acquired through a stock option exercise for cash, with the proposed sale date being October 14, 2026, on Nasdaq. The filing indicates a neutral impact and sentiment regarding this transaction.

Read original source

NRIX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.